Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3665742 | 1.00 | HRH3 (0.62) | HRH3KCNH2GPR119MCHR1SLC6A4 | |
| SCHEMBL3636321 | 0.93 | HRH3 (0.65) | HRH3KCNH2GPR119SLC6A4MGLL | |
| Hydrochloric Acid SCHEMBL3639931 | 0.92 | HRH3 (0.64) | HRH3KCNH2GPR119SLC6A4MGLL | |
| Tert-Butyl Formate SCHEMBL28784361 | 0.85 | HRH3 (0.55) | HRH3KCNH2GPR119PCSK9 | |
| Tert-Butyl Formate SCHEMBL27786378 | 0.84 | HRH3 (0.55) | HRH3KCNH2GPR119MCHR1MGLL | |
| SCHEMBL18924338 | 0.81 | HRH3 (0.70) | HRH3KCNH2GPR119MGLLKMT2A | |
| SCHEMBL3736663 | 0.81 | HRH3 (0.64) | HRH3KCNH2MCHR1SLC6A4SLC6A2 | |
| SCHEMBL3736662 | 0.81 | HRH3 (0.64) | HRH3KCNH2MCHR1SLC6A4SLC6A2 | |
| SCHEMBL8368604 | 0.81 | HRH3 (0.70) | HRH3KCNH2GPR119MGLLKMT2A | |
| SCHEMBL3731699 | 0.79 | HRH3 (0.88) | HRH3KCNH2GPR119MGLLABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008147945-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885KCNH2 581/4885GPR119 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.